Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach

Proteomics - Clinical Applications

Volumn 1, Issue 6, 2007, Pages 605-620

  Matharoo Ball, Balwir ^a   Ratcliffe, Lucy ^a   Lancashire, Lee ^a   Ugurel, Selma ^b,c   Miles, Amanda K ^a   Weston, Daniel J ^a   Rees, Robert ^a   Schadendorf, Dirk ^b,c   Ball, Graham ^a   Creaser, Colin S ^a  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biomarkers; MALDI; Mass spectrometry; Melanoma

Indexed keywords

ALPHA 1 ACID GLYCOPROTEIN PRECURSOR 1; ALPHA 1 ACID GLYCOPROTEIN PRECURSOR 2; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3 PRECURSOR 1; GLYCOPROTEIN; PEPTIDE; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL NEURAL NETWORK; BIOINFORMATICS; CANCER STAGING; CLUSTER ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; HUMAN; IMMUNOASSAY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MELANOMA; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS; VALIDATION PROCESS;

EID: 34548146655     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200700022     Document Type: Article

References (56)

1. Balch, C. M., Buzaid, A. C., Soong, S. J., Atkins, M. B. et al., Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 2001, 19, 3635-3648.
2. Ben-Porat, L., Panageas, K. S., Hanlon, C., Patel, A. et al., Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma. Cancer 2006, 106, 163-171.
3. Utikal, J., Schadendorf, D., Ugurel, S., Serological and immunohistochmical prognostic biomarkers of cutaneous malignancies. Arch. Dermatol. Res. 2007, Jan 13, [Epub ahead of print].
4. Djukanovic, D., Hofmann, U., Sucker, A., Rittgen, W. et al., Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res. 2000, 20, 2203-2207.
5. Miliotes, G., Lyman, G. H., Cruse, C. W., Puleo, C. et al., Evaluation of new putative tumor markers for melanoma. Ann. Surg. Oncol. 1996, 3, 558-563.
6. Mian, S., Ugurel, S., Parkinson, E., Schlenzka, I. et al., Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J. Clin. Oncol. 2005, 23, 5088-5093.
7. Hanash, S., Disease proteomics. Nature 2003, 422, 226-232.
8. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J. et al., Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 16, 572-577.
9. Hutchens, T. W., Yip, T. T., New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun. Mass Spectrom. 1993, 7, 576-580.
10. Koomen, J. M., Li, D., Xiao, L. C., Liu, T. C. et al., Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J. Proteome Res. 2005, 4, 972-981.
11. de Noo, M. E., Martens, B. J., Ozalp, A., Bladergroen, M. R. et al., Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur. J. Cancer 2006, 42, 1068-1076.
12. Traub, F., Feist, H., Kreipe, H. H., Pich, A., SELDI-MS-based expression profiling of ductal invasive and lobular invasive human breast carcinomas. Pathol. Res. Pract. 2005, 201, 763-770.
13. Mian, S., Ball, G., Hornbuckle, J., Holding, F. et al., A prototype methodology combining surface-enhanced laser desorption/ ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in vitro conditions. Proteomics 2003, 3, 1725-1737.
14. Finnskog, D., Jaras, K., Ressine, A., Malm, J. et al., High-speed biomarker identification utilizing porous silicon nanovial arrays and MALDI-TOF mass spectrometry. Electrophoresis 2006, 27, 1093-1103.
15. Adam, B. L., Qu, Y., Davis, J. W., Ward, M. D. et al., Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002, 62, 3609-3614.
16. Adkins, J. N., Varnum, S. M., Auberry, K. J., Moore, R. J. et al., Toward a human blood serum proteome: Analysis by multidimensional separation coupled with mass spectrometry. Mol. Cell. Proteomics 2002, 1, 947-955.
17. Tirumalai, R. S., Chan, K. C., Prieto, D. A., Issaq, H. J. et al., Characterization of the low molecular weight human serum proteome. Mol. Cell Proteomics 2003, 2, 1096-1103.
18. Koomen, J. M., Zhao, H., Li, D., Abbruzzese, J., Beggarly, K. et al., Diagnostic protein discovery using proteolytic peptide targeting and identification. Rapid Commun. Mass Spectrom. 2004, 18, 2537-2548.
19. Check, E., Proteomics and cancer: Running before we can walk? Nature 2004, 429, 496-497.
20. Veltri, R. W., Miller, M. C., An, G., Standardization, analytical validation, and quality control of intermediate endpoint biomarkers. Urology 2001, 57, 164-170.
21. Parekattil, S. J., Fisher, H. A., Kogan, B. A., Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer. J. Urol. 2003, 169, 917-920.
22. Ringner, M., Peterson, C., Microarray-based cancer diagnosis with artificial neural networks. Biotechniques 2003, Suppl., 30-35.
23. Lancashire, L., Schmid, O., Shah, H., Ball, G., Classification of bacterial species from proteomic data using combinatorial approaches incorporating artificial neural networks, cluster analysis and principal components analysis. Bioinformatics 2005, 15, 2191-2199.
24. Rumelhart, D. E., McClelland, J. L., Parallel Distributed Processing: Explorations in the Microstructure of Cognition, Volume 1: Foundations, The MIT Press, Cambridge 1986.
25. Ransohoff, D., Lessons from controversy: Ovarian cancer screening and serum proteomics. J. Natl. Cancer Inst. 2005, 97, 315-319.
26. Beggarly, K. A., Morris, J. S., Coombes, K. R., Reproducibility of SELDI-TOF protein patterns in serum: Comparing datasets from different experiments. Bioinformatics 2004, 22, 777-785.
27. Diamandis, E. P., van der Merwe, D. E., Plasma protein profiling by mass spectrometry for cancer diagnosis: Opportunities and limitations. Clin. Cancer Res. 2005, 11, 963-965.
28. Diamandis, E. R, Proteomic patterns to identify ovarian cancer: 3 years on. Expert Rev. Mol. Diagn. 2004, 4, 575-577.
29. Sorace, J. M., Zhan, M., A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 2003, 9, 24.
30. Pepe, M. S., Etzioni, R., Fang, Z., Potter, J. D. et al., Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 2001, 93, 1054-1061.
31. Dugue, B., Leppanen, E., Grasbeck, R., Preanalytical factors (biological variation) and the measurement of serum soluble intercellular adhesion molecule-1 in humans: Influence of the time of day, food intake, and physical and psychological stress. Clin. Chem. 1999 45, 1543-1547.
32. Ulmert, D., Becker, C., Nilsson, J. A., Piironen, T. et al., Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin. Chem. 2006 52, 235-239.
33. Banks, R. E., Stanley, A. J., Cairns, D. A., Barrett, J. H. et al., Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin. Chem. 2005 5, 1637-1649.
34. de Noo, M. E., Tollenaar, R. A., Ozalp, A., Kuppen, P. J. et al., Reliability of human serum protein profiles generated with C8 magnetic beads assisted MALDI-TOF mass spectrometry. Anal. Chem. 2005, 77, 7232-7241.
35. Semmes, O. J., Feng, Z., Adam, B. L., Banez, L. L. et al., Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin. Chem. 2005 51, 102-112.
36. Michiels, S., Koscielny, S., Hill, C., Prediction of cancer outcome with mcroarrays: a multiple random validation strategy. Lancet 2005, 365, 488-492.
37. Ferrari, L., Seraglia, R., Rossi, C. R., Bertazzo, A. et al., Protein profiles in sera of patients with malignant cutaneous melanoma. Rapid Commun. Mass Spectrom. 2000, 14, 1149-1154.
38. Ragazzi, E., Vogliardi, S., Allegri, G., Costa, C. V. L. et al., Cluster analysis of serum proteins in malignant cutaneous melanoma: search for disease markers. Rapid Commun. Mass Spectrom. 2003, 17, 1511-1515.
39. Seraglia, R., Vogliardi, S., Allegri, G., Comai, S. et al., Search for melanoma markers in plasma and serum samples. Eur. J. Mass Spectrom. 2005, 11, 353-360.
40. Kremmer, T., Szollosi, E., Boldizsar, M., Vincze, B. et al., Liquid chromatographic and mass spectrometric analysis of human serum acid alpha-1-glycoprotein. Biomed Chromatogr. 2004, 18, 323-329.
41. Duche, J. C., Urien, S., Simon, N., Malaurie, E. et al., Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer. Clin. Biochem. 2000, 33, 197-202.
42. Bleasby, A. J., Knowles, J. C., Cooke, N. J., Microheterogeneity of alpha 1-acid glycoprotein: Lack of discrimination between benign and malignant inflammatory disease of the lung. Clin. Chim. Acta. 1985, 150, 231-235.
43. Alexander, H., Stegner, A. L., Wagner-Mann, C., Du Bois, G. C. et al., Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin. Cancer Res. 2004, 10, 7500-7510.
44. Sarcione, E. J., Hepatic synthesis and secretory release of plasma alpha-2 (acute phase)-globulin appearing in malignancy. Cancer Res. 1967, 27, 2025-2033.
45. Sorensson, J., Matejka, G. L., Ohlson, M., Haraldsson, B., Human endothelial cells produce orosomucoid, an important component of the capillary barrier. Am. J. Physiol. 1999, 276, H530-H534.
46. Irmak, S., Tilki, D., Heukeshoven, J., Oliveira-Ferrer, L. et al., Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics 2005, 5, 4296-4304.
47. Carmeliet, R, Angiogenesis in health and disease. Nat. Med. 2003, 9, 653-660.
48. Jain, R. K., Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat. Med. 2001, 7, 987-989.
49. Villanueva, J., Shaffer, D. R., Philip, J., Chaparro, C. A. et al., Differential exoprotease activities confer tunor-specific serum prptidome patterns. J. Clin. Invest. 2006, 116, 271-284.
50. Liotta, L. A., Petricoin, E. F., Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J. Clin. Invest. 2006, 116, 26-30.
51. Warner, N. B., The Complement System, Mechanisms of Activation and Use as a Diagnostic Tool, Beckman Coulter Inc. 1998, C-1, pp. 10-11.
52. Tang, S., Zhou, W., Sheerin, N. S., Vaughan, R. W. et al., The complement system, mechanisms of activation and use as a diagnostic tool. J. Immunol. 1999, 162, 4336-4341.
53. Cole, D. S., Morgan, B. R, Beyond lysis: How complement influences cell fate. Clin. Sci. (Lond.) 2003, 104, 455-466.
54. Chang, J. T., Chen, L. C., Wei, S. Y, Chen, Y. J. et al., Increase diagnostic efficac by combined use of fingerprint markers in mass spectrometry-plasma peptidomes from nasopharyngal cancer aptients for example. Clin. Biochem. 2006, 39, 1144-1151.
55. Sheth, K., Bankey, P., The liver as an immune organ. Curr. Opin. Crit. Care 2001, 7, 99-104.
56. Fung, E. T., Yip, T. T., Lomas, L., Wang, Z. et al., Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int. J. Cancer 2005, 115, 783-789.